CorVel Corporation (NASDAQ: CRVL) — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2021. The request metadata says “2019 Q4,” but the supplied filing is CorVel’s FY2021 annual report, not a 2019 quarterly filing.
Business context
CorVel provides workers’ compensation, auto, liability and group-health claims management and medical cost-containment services. Its offerings include patient management and network solutions, supported by proprietary claims and bill-review technology. It reports one operating segment, managed care.
Financial performance and liquidity
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue | $552.6 million | $592.2 million | Down 6.7% |
| Gross profit / margin | $123.6 million / 22.4% | $125.9 million / 21.3% | Profit down 1.8%; margin up 1.1 percentage points |
| Income before taxes | $59.2 million | $60.7 million | Down 2.5% |
| Net income / diluted EPS | $46.4 million / $2.55 | $47.4 million / $2.55 | Net income down 2.2%; EPS unchanged |
| Operating cash flow | $94.4 million | $80.8 million | Up $13.6 million |
| Cash and working capital at year-end | $139.7 million / $106.5 million | $83.2 million / $75.3 million | Cash and working capital increased |
Net margin was 8.4%, versus 8.0% in FY2020. Cash provided by operations benefited in part from deferred payroll-tax deposits under the CARES Act. The company reported virtually no interest-bearing debt historically; its revolving credit facility expired in September 2019 and was not renewed. Year-end total liabilities included $54.7 million of lease liabilities. Contractual obligations were $60.4 million, primarily leases and software licenses.
FY2021 revenue comprised $368.9 million from patient management (down 4.6%) and $183.8 million from network solutions (down 10.5%). Patient management represented 66.7% of revenue, up from 65.3%. The company attributed the revenue decline mainly to lower bill volume: bills reviewed fell 22% and workers’ compensation claims fell 2.5%; higher revenue per bill partly offset the impact.
Fourth-quarter FY2021 revenue was $145.5 million, gross profit $35.7 million and net income $14.8 million, compared with $147.0 million, $30.7 million and $11.7 million, respectively, in fourth-quarter FY2020. Quarterly revenue rose sequentially through FY2021 after the pandemic-related downturn.
Material changes and notable items
- COVID-19 reduced claims and bill volumes, disrupted service delivery and led to lower revenue. CorVel reduced headcount by 10% beginning in late FY2020, curtailed discretionary spending and temporarily paused share repurchases from March 21 to June 14, 2020.
- Operating cash flow rose partly because the company deferred $10.4 million of payroll-tax deposits; half was due by the end of calendar 2021 and half by the end of calendar 2022.
- Capital spending fell: investing cash outflow was $17.2 million versus $32.4 million in FY2020. Financing cash outflow was $20.6 million, including $32.7 million spent repurchasing 367,961 shares at an average $88.79.
- At March 31, 2021, 36.7 million shares had been repurchased cumulatively for $564.4 million. In May 2021, the board increased the lifetime authorization to 38 million shares.
- The company remeasured several lease obligations as it anticipated a lasting shift toward remote work; the balance-sheet reduction in lease assets and liabilities had an immaterial income-statement impact.
Outlook, risks and contingencies
Management said sequential revenue had increased in the September, December and March 2021 quarters and expected the trend to continue in 2021, particularly as vaccines were distributed. This is not quantified formal guidance. CorVel cautioned that the pandemic, economic recovery, future outbreaks and vaccine effectiveness remain uncertain, and expected COVID-19 to continue adversely affecting future results, including revenue.
Key risks include lower employment and claim volumes, customer contract losses or reduced outsourcing, competition and pricing pressure, labor and benefit costs, regulatory changes, cybersecurity incidents, technology investment needs, and litigation or liability exposure. The company reported ordinary-course litigation and said its resolution was not expected to be material in aggregate. No customer generated 10% or more of revenue, although one customer represented at least 10% of accounts receivable at year-end. The auditor issued unqualified opinions on the financial statements and internal control; revenue recognition was identified as a critical audit matter because certain bill-review and directed-care revenues require estimation.
Important facts for investors to verify
- Confirm the intended period: this filing covers FY2021, not 2019 Q4.
- Track whether sequential revenue recovery continued and whether bill volumes and workers’ compensation claims rebounded.
- Assess the sustainability of gross-margin improvement and earnings while annual revenue declined.
- Monitor collection risk, including the significant receivable concentration, and the repayment schedule for deferred payroll taxes.
- Review future repurchases, liquidity needs and lease commitments alongside management’s remote-work and capital-spending plans.
- Evaluate the duration and financial effects of COVID-19, regulatory changes, cybersecurity exposure and litigation risks.